在患有严重喘和持久性气流阻塞的患者中,tzepelumab的有效性
Elliot Israel1, Mario Castro2, Christopher S Ambrose3
1Pulmonary and Critical Care Medicine, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
ERJ open research
|November 26, 2024
概括
在患有严重,不受控制的喘和持久性气流阻塞 (PAO) 的患者中,Tezepelumab显著改善了肺功能,并减少了喘恶化. 这种生物疗法为管理难以治疗的喘病例提供了新的选择.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 临床药理学 临床药理学
背景情况:
- 持久性气流阻塞 (PAO) 在严重的,不受控制的喘中提出了治疗挑战.
- 泰泽佩卢马布向胸膜层淋巴蛋白 (TSLP),这是喘病原体中的关键细胞因子.
研究的目的:
- 为了评估tezepelumab在患有PAO的严重,不受控制的喘患者的疗效.
- 为了评估tezepelumab治疗的肺功能改善和恶化率降低.
主要方法:
- 对PATHWAY (第2b期) 和NAVIGATOR (第3期) 研究进行了特设后期分析.
- 患者在52周内每4周接受特泽佩卢马布 (210毫克) 或安慰剂.
- 在患有和没有PAO的患者中,评估了支气管扩展前FEV1和年化喘恶化率 (AAER) 的变化.
主要成果:
- 在患有PAO (0.24L vs 0.07L) 和没有PAO (0.20L vs 0.12L) 的患者中,Tezepelumab比安慰剂更能改善支气管扩展前FEV1.
- 与安慰剂相比,Tezepelumab在患有PAO的患者中减少了61%的AAER,在没有PAO的患者中减少了56%.
- 较高比例的PAO患者在基线达到PAO解决52周的tezepelumab (12.1%) 与安慰剂 (6.6%) 相比.
结论:
- 与安慰剂相比,Tezepelumab在肺功能 (FEV1) 中表现出显著的改善.
- 不管PAO状态如何,Tezepelumab有效地减少了严重,不受控制的喘患者的喘恶化.
- 德泽佩卢马布为严重喘提供了一个有前途的治疗选择,包括持续阻塞空气流的病例.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
245
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
245
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
218
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
218
COPD: Management Using Bronchodilators and Corticosteroids
179
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
179
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K


